Anti-ADAMTS13 Autoantibodies in Immune-Mediated Thrombotic Thrombocytopenic Purpura
Autoantibodies to ADAMTS13 are at the center of pathology of the immune-mediated thrombotic thrombocytopenic purpura. These autoantibodies can be either inhibitory (enzymatic function) or non-inhibitory, resulting in protein depletion. Under normal physiologic conditions, antibodies are generated in...
Saved in:
| Main Authors: | Michael R. Snyder, Robert W. Maitta |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-03-01
|
| Series: | Antibodies |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4468/14/1/24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical significance of measuring ADAMTS-13, its inhibitor and von Willebrand factor in obstetric and gynecological practice
by: K. N. Grigoreva, et al.
Published: (2021-03-01) -
Prophylactic use of recombinant ADAMTS-13 during pregnancy for congenital thrombotic thrombocytopenic purpura
by: Éloïse Colliou, et al.
Published: (2025-01-01) -
Congenital Thrombotic Thrombocytopenic Purpura: Atypical Presentation And First ADAMTS 13 Mutation In A Tunisian Child
by: aida borgi
Published: (2013-06-01) -
Clinical presentation and treatment of thrombotic thrombocytopenic purpura - analysis of recent diagnostic and therapeutic methods
by: Jan Szwech, et al.
Published: (2025-03-01) -
Caplacizumab in the Treatment of Patients with Recurrent Thrombotic Thrombocytopenic Purpura (TTP)
by: Mihaela-Sabrina HERDEA, et al.
Published: (2025-03-01)